Error in Funding/Support | Oncology | JAMA Oncology | JAMA Network
[Skip to Navigation]
Sign In
Views 272
Citations 0
Correction
May 2021

Error in Funding/Support

JAMA Oncol. 2021;7(5):785. doi:10.1001/jamaoncol.2021.1616

In the Brief Report titled “Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma,”1 published online March 25, 2021, a grant from the New York University’s Specialized Program of Research Excellence in Melanoma was omitted from the Funding/Support section. This article has been corrected online.

References
1.
Patrinely  JR  Jr, Johnson  R, Lawless  AR,  et al.  Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma.   JAMA Oncol. Published online March 25, 2021. doi:10.1001/jamaoncol.2021.0051PubMedGoogle Scholar
×